A Glimmer in the Dark: An Oral Pill Shows Promise Against Huntington's

BOSTON, MA – September 15, 2026 – For families ravaged by Huntington's disease, hope has often felt like a foreign currency, devalued by decades of clinical trial failures and the relentless progression of a fatal neurodegenerative disorder. But today, that currency is surging. Skyhawk Therapeutics, a Boston-based biotechnology firm, announced final results from a 15-month study that are nothing short of remarkable, suggesting an investigational oral pill may not only slow the disease but, in some measures, reverse its course.

The data, from a Phase 1/2 trial of the drug SKY-0515, shows that patients on the treatment improved across a composite scale measuring function, movement, and cognition. While a matched group of untreated patients from historical data declined as expected, the SKY-0515 group ended the study, on average, better than when they started. It’s a result that has sent a jolt of cautious electricity through a community accustomed to bracing for the worst.

The Human Equation of a Devastating Disease

Huntington’s is a uniquely cruel disease. Caused by a single faulty gene, it stalks families through generations, carrying a 50% chance of inheritance. It slowly erodes a person's physical and mental abilities, leading to involuntary movements (chorea), cognitive decline, and severe psychiatric disturbances. With over 40,000 symptomatic people in the U.S. and no approved therapies to alter its course, the diagnosis is a death sentence delivered in slow motion.

The current standard of care is a patchwork of medications to manage symptoms, none of which touch the underlying pathology—the buildup of a toxic mutant huntingtin protein (mHTT) that destroys brain cells. This is the context in which Skyhawk's announcement lands. The company reported that after 15 months, patients taking SKY-0515 showed a statistically significant 1.59-point positive difference on the Composite Unified Huntington's Disease Rating Scale (cUHDRS) compared to an external control group.

To the layperson, it’s a clinical-sounding number. To a patient, it represents tangible gains in daily life. The scale’s components measure a person's ability to manage finances and daily tasks, control their movements, and think clearly. On every single one of these components—functional capacity, motor scores, and cognitive tests—patients taking SKY-0515 did significantly better than the control group.

"For almost two decades, I have fought as an advocate for Huntington's disease patients, bearing witness to countless heartbreaking trial setbacks that have let our families down," said Katie Jackson, Chief Executive Officer of Help 4 HD International, in a statement. "To finally see results like these--patients experiencing improvements in function, movement, and cognition -- is what we have been hoping and waiting for."

What makes the results particularly resonant is the drug's form: a once-daily pill. This stands in stark contrast to more invasive experimental approaches that require spinal taps or even brain surgery, offering a path to treatment that could be accessible to patients in rural communities and those unable to travel to specialized centers.

The Science of Splicing

The promise of SKY-0515 lies in its sophisticated, dual-pronged attack on the disease's core biology. The drug is a small molecule RNA splicing modifier, a product of Skyhawk’s proprietary SKYSTAR® platform. In simple terms, it intervenes at the genetic level to correct the messaging that leads to disease.

First, it has shown consistent average reductions of the toxic mHTT protein by more than 60% in patients at the higher dose. This directly targets the primary driver of neurodegeneration. Second, it reduces another protein, PMS1, by over 25%. PMS1 is a key driver of something called somatic instability, a process where the genetic defect worsens in a patient’s cells over their lifetime, accelerating the disease. By tackling both, SKY-0515 addresses both the cause and an accelerant of Huntington's.

"Skyhawk's Phase 1/2 results are extremely encouraging clinical data," said Dr. Samuel Frank, a leading Huntington’s expert at Beth Israel Deaconess Medical Center, who was quoted in the company's release. "SKY-0515's dual reduction of mHTT and PMS1 addresses two core pathogenic mechanisms of Huntington's disease. If these findings are confirmed... the impact on people living with HD across the world could be profound."

This success serves as a powerful validation for Skyhawk's underlying technology. The company is betting that its SKYSTAR® platform can generate similar RNA-targeting pills for a host of other currently untreatable neurological conditions. "The data from SKY-0515 confirms that the possibilities of extraordinary novel drugs generated by Skyhawk's SKYSTAR platform are very exciting," stated Sergey Pauskin, the company’s Co-founder and Head of R&D.

The Long Road from Promise to Pharmacy

Despite the justifiable excitement, the road ahead is long and paved with scientific rigor. The Phase 1/2 study, while promising, was small, with only 15 patients remaining in the analysis at the final 15-month timepoint. The comparison was made not against a live placebo group, but a carefully selected "external control" group from natural history databases. While this is a common and accepted practice in early-stage rare disease trials, it is not the gold standard of a randomized, placebo-controlled study.

That gold-standard test is already underway. The global Phase 2/3 FALCON-HD pivotal program has enrolled over 200 patients across ten countries, with plans to enroll approximately 600 in total. This large-scale study will pit SKY-0515 directly against a placebo in a double-blind fashion, providing the definitive evidence that regulators like the FDA will require for approval.

Dr. Frank's cautious optimism underscores this reality. He noted that the consistent effects are an "exciting step forward" but crucially added that they "need to be further studied in ongoing placebo-controlled studies."

For the thousands of families living in the shadow of Huntington's, the wait is agonizing. But for the first time in a long time, the results from a small trial of an oral pill have allowed a fragile, yet powerful, sense of hope to take root. The journey is far from over, but today, the destination—a world with an effective treatment for Huntington's disease—feels closer than ever.